Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04415866 · ClinicalTrials.gov registry record · NA

Generalized Hypersensitivity in Patients With Fibromyalgia Syndrome

A NA study of Fibromyalgia, sponsored by University of Florida.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT04415866: Completed NA study of Fibromyalgia, sponsored by University of Florida.

NCT04415866 is a NA study of Fibromyalgia that has completed, run by University of Florida. The registered enrollment target is 30 participants, below the 179-participant average among 76 other Fibromyalgia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04415866, a NA study of Fibromyalgia, has completed, sponsored by University of Florida.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Fibromyalgia (FM) is a chronic musculoskeletal pain disorder with unknown causes. Our previous studies showed abnormal sensations of second pain (wind-up), indicating central hypersensitivity as an important mechanism of FM. Triggering events have been implicated as the cause of central hypersensitivity.

Primary Outcome

FM and control subjects will provide verbal ratings of experimental pain stimuli. For this purpose a numerical ratings scale (0-100) will be used ranging from "no sensation" to the "most intense sensation possible". All measures will be obtained in triplicates and the averages will be used for statistical comparisons.

Conditions Studied

Interventions

  • BEHAVIORAL Paced Auditory Serial Addition task (PASAT)

Study Locations (1)

Florida

  • University of Florida - Gainesville

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2020-08-28
Est. Completion 2020-12-11
Phase NA
University of Florida

1,106 total trials

What the finished NCT04415866 record still lists

NCT04415866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 179-participant average among 76 other Fibromyalgia trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Fibromyalgia appearing as the primary indexed condition, and to 1 intervention - of which Paced Auditory Serial Addition task (PASAT) is the first listed.

NCT04415866 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT04415866 about?

NCT04415866 is a clinical study titled "Generalized Hypersensitivity in Patients With Fibromyalgia Syndrome". Fibromyalgia (FM) is a chronic musculoskeletal pain disorder with unknown causes. Our previous studies showed abnormal sensations of second pain (wind-up), indicating central hypersensitivity as an important mechanism of FM. Triggering events have been implicated as the cause of central hypersensiti...

What is the current status of trial NCT04415866?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2020-08-28. Estimated completion is 2020-12-11.

What conditions does trial NCT04415866 study?

This clinical trial studies the following conditions: Fibromyalgia.

What interventions are being tested in trial NCT04415866?

The interventions under investigation include: Paced Auditory Serial Addition task (PASAT) (BEHAVIORAL).

Who is sponsoring clinical trial NCT04415866?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04415866 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fibromyalgia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04415866's enrollment target sits among peer trials

30 60th of 76 higher than 16 of 76 other Fibromyalgia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Fibromyalgia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04415866, the US trial registry maintained by the National Library of Medicine. NCT04415866 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.